Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40261-021-01059-w.pdf
Reference37 articles.
1. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886–95.
2. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
3. Martelletti P. Erenumab is effective in reducing migraine frequency and improving physical functioning. BMJ Evid-Based Med. 2019;24(2):76.
4. Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs. 2017;31(6):483–5.
5. Clougherty JE, Kinnee EJ, Cardet JC, Mauger D, Bacharier L, Beigelman A, et al. Geography, generalisability, and susceptibility in clinical trials. Lancet Respir Med. 2021;9(4):330–2.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Are we closer to achieving precision medicine for migraine treatment? A narrative review;Cephalalgia;2024-09
2. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis;European Journal of Pharmacology;2024-08
3. Erenumab efficacy in migraine headache prophylaxis: A systematic review;International Immunopharmacology;2023-04
4. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy;Cephalalgia;2023-02
5. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months;The Journal of Headache and Pain;2023-01-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3